16th Jan 2007 07:01
Sinclair Pharma PLC16 January 2007 Ashbourne Pharmaceuticals, part of the Sinclair Pharma plc group, launches ' product fostering' concept with Arlevert deal 16 January 2007, Godalming, UK. Sinclair Pharma plc (SPH.L), the specialtypharmaceutical company, announces that its UK subsidiary AshbournePharmaceuticals has signed a marketing agreement with the German company HennigArzneimittel GmbH for the vertigo product Arlevert, and will today launch theproduct. The Arlevert deal launches Ashbourne's 'product fostering' concept, offeringcompanies an initial low-risk product sales and evaluation period in the UKdispensing doctor market. After this initial fostering period, there is theopportunity to expand product sales to the secondary care market in the UK andEurope through Sinclair's other sales channels. Product fostering also providesa number of other services; as part of the Arlevert agreement, Ashbourne hasbeen instrumental in gaining reimbursement, performing market research anddeveloping the product sales and marketing strategy. The UK launch for Arlevert is initially intended to generate sales withinAshbourne's traditional customer group, UK dispensing doctors. However in thelong term it is intended to foster the broader UK market. Sinclair is buildinga UK specialist salesforce to complement its European sales presence; these UKspecialist salespeople will be able to co-promote products alongside Ashbourne. Ashbourne has a successful track record of co-promoting products into the nichedispensing doctor sector in the UK. The product fostering concept has beendeveloped since Ashbourne was acquired by Sinclair in September 2006. LeslieGalloway, CEO of Ashbourne Pharmaceuticals, said: "Fostering offers partner companies a low risk and complete facility to launchand evaluate products in the UK market. We have already seen significantinterest in the idea; many companies are interested in Ashbourne as a precursorto broader UK sales, and also potentially for European sales. We see manysynergies with Sinclair's growing European specialist salesforce." Danilo Casadei Massari, VP Corporate Development of Sinclair, said: "Product fostering meets the needs of many companies wanting to research andtest their product in the UK. Ashbourne offers a market-entry service, andsynergies with the Sinclair Group mean that there are roll-out opportunities forsales and marketing activities in other EU markets. In 2007, Sinclair aims tocomplete the establishment and consolidation of its specialist salesforces inthe five key EU territories and in the Nordic region, strengthening our positionas an attractive commercial partner for Europe. Arlevert is one of the first products in a specialist portfolio that will becompleted within 2007 and enable Sinclair to start its commercial organizationin the UK" - ends - Enquiries:Capital MS&L Tel: +44 (0) 207 307 5330Mary Clark, Halina Kukula Sinclair Pharma plc Tel: +44 (0) 1483 410600Michael Flynn, CEOZoe McDougall Tel: +44 (0) 7973 792 520John Barrington-Carver Tel: +44 (0) 7831 655 630 Notes to editors: Arlevert and Vertigo Vertigo is a false sense of motion or spinning that can cause dizziness ornausea. It can occur as a result of a problem with the central nervous system("central vertigo") or if there is a problem with the inner ear ("peripheralvertigo"). Arlevert is indicated to treat both central and peripheralvestibular vertigo and will be the only combination product available in the UKto effectively do so. Hennig Arzneimittel GmbH Based in Florsheim, Hennig Arzneimittel is one of the oldest research-basedprivate pharmaceutical companies in Germany. Hennig combines a domestic salesforce and the most advanced manufacturing facilities to address the Germanhealthcare market. Their research and development facilities focus on anevidence based approach to the development of pharmaceutical products. Ashbourne Pharmaceuticals Ltd Ashbourne Pharmaceuticals is a UK sales and marketing organisation, with asuccessful track record of co-promoting pharmaceutical products to UK dispensingdoctors for more than 20 years. Ashbourne was acquired by Sinclair Pharma plcin September 2006. Dispensing doctors provide dispensary services for patients who live more thanone mile from a retail pharmacy. They need to generate an income from thesedispensing services in order to cover associated costs. Ashbourne co-promotesspecific products to these doctors, also providing them with unique products andservices that support their dispensing practice. Dispensing doctors account foran estimated 18% of the UK primary care market by value. Ashbourne is currently seeking rights to products that may be sold by both theexisting Ashbourne existing sales force, and in the future the UK Sinclairsalesforce (targeting other healthcare professionals such as specialists). Sinclair Pharma plc Sinclair Pharma plc is an international specialty pharmaceutical company. Ithas a growing sales and marketing operation that is already present in France,Italy, UK, Spain and Portugal, and a complementary marketing partner networkthat spans more than 60 countries. Sinclair has proven expertise in acquiring or developing commercially attractiveand undervalued products, registering these products and bringing them to marketwithin a short time frame. The company focuses on niche therapeutic areas andits current portfolio includes products for dermatological conditions and oralhealth. "Safe Harbor" Statement under the US Private Securities Litigation Reform Act of1995: Some or all of the statements in this document that relate to futureplans, expectations, events, performances and the like are forward-lookingstatements, as defined in the US Private Securities Litigation Reform Act of1995. Actual results of events could differ materially from those described inthe forward- looking statements due to a variety of factors. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Sinclair Pharma